Developments in the Management of Metastatic HER2-Positive Breast Cancer: A Review.
Approximately 20% of breast cancers overexpress human epidermal growth factor receptor 2 (HER2), providing an actionable target for many different therapies. In the metastatic setting, prognosis has improved greatly with the use of anti-HER2 drugs such as trastuzumab, pertuzumab, and trastuzumab-emt...
| Publicado en: | Current Oncology Vol. 29; no. 4; pp. 2539 - 2550 |
|---|---|
| Autores principales: | , |
| Formato: | Journal Article |
| Publicado: |
MDPI
Apr2022
|
| Acceso en línea: | Ver este registro en EBSCOhost |